Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: Toward eradication of CML

Molecular Pharmaceutics

Volumn 10, Issue 9, 2013, Pages 3475-3483

  Miller, Geoffrey D ^a   Woessner, David W ^a   Sirch, Monika J ^b   Lim, Carol S ^a  

^a UNIVERSITY OF UTAH   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bcr Abl; CCmut3; CML; combination therapy; ponatinib; T315I

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CASPASE 7; PONATINIB; PROTEIN TYROSINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN TARGETING;

APOPTOSIS; CASPASE 3; CASPASE 7; CELL PROLIFERATION; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NECROSIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84883573274     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400323c     Document Type: Article

References (41)

1. Bartram, C. R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia Nature 1983, 306 (5940) 277-280
2. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 1973, 243 (5405) 290-293
3. McWhirter, J. R.; Galasso, D. L.; Wang, J. Y. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins Mol. Cell. Biol. 1993, 13 (12) 7587-7595
4. Zhao, X.; Ghaffari, S.; Lodish, H.; Malashkevich, V. N.; Kim, P. S. Structure of the Bcr-Abl oncoprotein oligomerization domain Nat. Struct. Biol. 2002, 9 (2) 117-120
5. Woessner, D. W.; Lim, C. S.; Deininger, M. W. Development of an effective therapy for chronic myelogenous leukemia Cancer J. 2011, 17 (6) 477-486
6. Dixon, A. S.; Miller, G. D.; Bruno, B. J.; Constance, J. E.; Woessner, D. W.; Fidler, T. P.; Robertson, J. C.; Cheatham, T. E., III; Lim, C. S. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis Mol. Pharmaceutics 2012, 9 (1) 187-195
7. Hazlehurst, L. A.; Bewry, N. N.; Nair, R. R.; Pinilla-Ibarz, J. Signaling networks associated with BCR-ABL-dependent transformation Cancer Control 2009, 16 (2) 100-107
8. Ren, R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model Oncogene 2002, 21 (56) 8629-8642
9. Liu, J.; Campbell, M.; Guo, J. Q.; Lu, D.; Xian, Y. M.; Andersson, B. S.; Arlinghaus, R. B. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon Oncogene 1993, 8 (1) 101-9
10. Sierra, J. R.; Cepero, V.; Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Mol. Cancer 2010, 9, 75
11. O'Hare, T.; Zabriskie, M. S.; Eiring, A. M.; Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia Nat. Rev. Cancer 2012, 12 (8) 513-526
12. O'Hare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 2007, 110 (7) 2242-2249
13. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A., III; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 2009, 16 (5) 401-412
14. Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl- N -{4-[(4-methylpiperazin- 1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 2010, 53 (12) 4701-4719
15. Eide, C. A.; Zabriskie, M. S.; Adrian, L. T.; Lange, T.; Deininger, M. W.; Druker, B. J.; O'Hare, T. Resistance profiling of BCR-ABL compound mutations linked to tyrosine kinase inhibitor therapy failure in chronic myeloid leukemia [abstract] Blood 2011, 118 (21) 1416
16. Khorashad, J. S.; Kelley, T. W.; Szankasi, P.; Mason, C. C.; Soverini, S.; Adrian, L. T.; Eide, C. A.; Zabriskie, M. S.; Lange, T.; Estrada, J. C.; Pomicter, A. D.; Eiring, A. M.; Kraft, I. L.; Anderson, D. J.; Gu, Z.; Alikian, M.; Reid, A. G.; Foroni, L.; Marin, D.; Druker, B. J.; O'Hare, T.; Deininger, M. W. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships Blood 2013, 121 (3) 489-498
17. Shami, P. J.; Deininger, M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy Leukemia 2012, 26 (2) 214-224
18. Neelakantan, P.; Marin, D.; Laffan, M.; Goldman, J.; Apperley, J.; Milojkovic, D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy Haematologica 2012, 97 (9) 1444
19. Cortes, J. E.; Kantarjian, H.; Shah, N. P.; Bixby, D.; Mauro, M. J.; Flinn, I.; O'Hare, T.; Hu, S.; Narasimhan, N. I.; Rivera, V. M.; Clackson, T.; Turner, C. D.; Haluska, F. G.; Druker, B. J.; Deininger, M. W.; Talpaz, M. Ponatinib in refractory Philadelphia chromosome-positive leukemias New Engl. J. Med. 2012, 367 (22) 2075-2088
20. Dixon, A. S.; Pendley, S. S.; Bruno, B. J.; Woessner, D. W.; Shimpi, A. A.; Cheatham, T. E., III; Lim, C. S. Disruption of Bcr-Abl coiled coil oligomerization by design J. Biol. Chem. 2011, 286 (31) 27751-27760
21. Maru, Y.; Witte, O. N. The BCR gene encodes a novel serine/threonine kinase activity within a single exon Cell 1991, 67 (3) 459-468
22. Kin, Y.; Li, G.; Shibuya, M.; Maru, Y. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome J. Biol. Chem. 2001, 276 (42) 39462-39468
23. Demehri, S.; O'Hare, T.; Eide, C. A.; Smith, C. A.; Tyner, J. W.; Druker, B. J.; Deininger, M. W. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis Leukemia 2010, 24 (1) 226-229
24. Miao, Y. J.; Wang, J. Y. Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase J. Biol. Chem. 1996, 271 (37) 22823-22830
25. Van Etten, R. A.; Jackson, P. K.; Baltimore, D.; Sanders, M. C.; Matsudaira, P. T.; Janmey, P. A. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity J. Cell Biol. 1994, 124 (3) 325-340
26. Hantschel, O.; Wiesner, S.; Guttler, T.; Mackereth, C. D.; Rix, L. L.; Mikes, Z.; Dehne, J.; Gorlich, D.; Sattler, M.; Superti-Furga, G. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl Mol. Cell 2005, 19 (4) 461-473
27. Preyer, M.; Vigneri, P.; Wang, J. Y. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL PloS One 2011, 6 (2) e17020
28. Dixon, A. S.; Constance, J. E.; Tanaka, T.; Rabbitts, T. H.; Lim, C. S. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs Pharm. Res. 2012, 29 (4) 1098-1109
29. Lee, J. C.; Hapel, A. J.; Ihle, J. N. Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line J. Immunol. 1982, 128 (6) 2393-2398
30. Garner, A. P.; Anjum, R.; Vodala, S.; Schrock, A.; Zhou, T.; Clackson, T.; Gozgit, J. M.; Rivera, V. M. Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST AACR Annual Meeting Abstracts 2013, 3394
31. Ben-Neriah, Y.; Daley, G. Q.; Mes-Masson, A. M.; Witte, O. N.; Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene Science 1986, 233 (4760) 212-214
32. Sherbenou, D. W.; Hantschel, O.; Turaga, L.; Kaupe, I.; Willis, S.; Bumm, T.; Press, R. D.; Superti-Furga, G.; Druker, B. J.; Deininger, M. W. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia Leukemia 2008, 22 (6) 1184-1190
33. La Rosee, P.; Corbin, A. S.; Stoffregen, E. P.; Deininger, M. W.; Druker, B. J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) Cancer Res. 2002, 62 (24) 7149-7153
34. Gozgit, J. M.; Wong, M. J.; Wardwell, S.; Tyner, J. W.; Loriaux, M. M.; Mohemmad, Q. K.; Narasimhan, N. I.; Shakespeare, W. C.; Wang, F.; Druker, B. J.; Clackson, T.; Rivera, V. M. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies Mol. Cancer Ther. 2011, 10 (6) 1028-1035
35. Woessner, D. W.; Lim, C. S. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation Mol. Pharm. 2013, 10 (1) 270-277
36. Razzak, M. Haematology: Ponatinib: the next TKI challenge Nat. Rev. Clin. Oncol. 2013, 10 (2) 65
37. Mian, A. A.; Oancea, C.; Zhao, Z.; Ottmann, O. G.; Ruthardt, M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL Leukemia 2009, 23 (12) 2242-2247
38. Hantschel, O.; Superti-Furga, G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat. Rev. Mol. Cell Biol. 2004, 5 (1) 33-44
39. Baskiewicz-Masiuk, M.; Machalinski, B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells Eur. J. Haematol. 2004, 72 (6) 420-429
40. Grimley, P. M.; Dong, F.; Rui, H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation Cytokine Growth Factor Rev. 1999, 10 (2) 131-157
41. Schaller-Schoenitz, M.; Dallmann, I.; Ganser, A.; Scherr, M.; Eder, M. Function of STAT5 Isoforms in Bcr-Abl Positive Cells. ASH Annual Meeting Abstracts, 2011.